Company Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 09/02/2026 GMT			5-day change	1st Jan Change
7.132 ^USD	-0.11%		-10.85%	-50.58%

01-27	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome	CI
01-20	Quoin, Inc. Announces Application for Breakthrough Medicine Designation with the SFDA for QRX003	CI

Business description: Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâ€™s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Number of employees: 4

Sales by Activity: Quoin Pharmaceuticals, Ltd.

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)

See all business segments

Executive Committee: Quoin Pharmaceuticals, Ltd.

Manager	Title	Age	Since
Denise Carter COO	Chief Operating Officer	57	27/10/2021
Michael Myers CEO	Chief Executive Officer	64	27/10/2021
Sally Lawlor DFI	Director of Finance/CFO	43	17/08/2025

See QUOIN PHARMACEUTICALS, LTD. governance

Composition of the Board of Directors: Quoin Pharmaceuticals, Ltd.

Director	Title	Age	Since
Michael Sember BRD	Director/Board Member	-	27/10/2021
Dennis Langer BRD	Director/Board Member	74	27/10/2021
Joseph Cooper BRD	Director/Board Member	68	27/10/2021
Anthony Culverwell BRD	Director/Board Member	69	27/10/2021
Michael Myers CHM	Chairman	64	27/10/2021
Denise Carter BRD	Director/Board Member	57	27/10/2021
Natalie Leong BRD	Director/Board Member	41	27/10/2021

Composition of the Board of Directors

Shareholders: Quoin Pharmaceuticals, Ltd.

Name	Equities	%	Valuation
Ikarian Capital LLC 25.21 %	211,538	25.21 %	2 M $
Stonepine Capital Management LLC 11.14 %	93,460	11.14 %	674 314 $
abrdn, Inc. 8.939 %	75,000	8.939 %	541 125 $
abrdn, Inc. 8.939 %	75,000	8.939 %	541 125 $
Millennium Management LLC 6.476 %	54,331	6.476 %	391 998 $

Name	Equities	%	Valuation
Michael Myers 2.053 %	602,805	2.053 %	4 M $
Denise Carter 2.052 %	602,630	2.052 %	4 M $
Dennis Langer 1.806 %	530,355	1.806 %	4 M $
Gordon Dunn 0.5144 %	151,060	0.5144 %	1 M $
Anthony Culverwell 0.3416 %	100,317	0.3416 %	723 787 $

List of QUOIN PHARMACEUTICALS, LTD. shareholders

Company details: Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals Ltd.

42127 Pleasant Forest Court

20148-7349, Ashburn

http://www.quoinpharma.com

address Quoin Pharmaceuticals, Ltd.(QNRX)

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
QUOIN PHARMACEUTICALS, LTD.	-0.11%	-10.85%	-34.98%	-99.03%	5.98M
LONZA GROUP AG	+1.32%	+0.27%	-13.55%	-3.72%	47.17B
BEONE MEDICINES AG	-1.43%	+1.12%	+56.09%	+40.18%	38.6B
CELLTRION, INC.	+4.55%	+13.30%	+33.18%	+51.67%	34.53B
IQVIA HOLDINGS INC.	+2.76%	-16.68%	-7.43%	-16.34%	32.68B
REVOLUTION MEDICINES, INC.	-0.77%	-0.43%	+129.30%	+283.13%	18.7B
MEDPACE HOLDINGS, INC.	-2.16%	-9.83%	+49.77%	+135.13%	14.94B
Average	+0.60%	-1.68%	+30.34%	+55.86%	26.66B
Weighted average by Cap.	+1.13%	-1.07%	+29.95%	+53.26%